NICE recommends inhaled antibacterials in cystic fibrosis

Inhaled formulations of two antibiotics can be prescribed on the NHS for patients with cystic fibrosis, NICE has ruled.

The primary cause of death in cystic fibrosis is respiratory failure precipitated by chronic pulmonary infection caused by Pseudomonas aeruginosa (pictured) | SCIENCE PHOTO LIBRARY
The primary cause of death in cystic fibrosis is respiratory failure precipitated by chronic pulmonary infection caused by Pseudomonas aeruginosa (pictured) | SCIENCE PHOTO LIBRARY

The tobramycin dry powder inhaler (TOBI Podhaler) is recommended for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

Patients are eligible for treatment if nebulised tobramycin is considered appropriate, ie, colistimethate sodium is contraindicated, is not tolerated or has not produced an adequate response, and only if the manufacturer supplies the product with the discount agreed as part of the patient access scheme.

NICE also recommends colistimethate sodium powder for inhalation (Colobreathe) for patients with chronic P. aeruginosa infection who would benefit from continued colistimethate treatment but who do not tolerate the drug in nebulised form and would therefore be considered for tobramycin therapy. Again, NICE has specified that the drug must be provided with the discount agreed as part of the patient access scheme. However, Colobreathe has yet to be launched in the UK.

NICE guidance on inhaled tobramycin and colistimethate

Follow MIMS on Twitter


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases